tradingkey.logo

AxoGen Inc

AXGN
31.980USD
+0.280+0.88%
Close 12/19, 16:00ETQuotes delayed by 15 min
1.47BMarket Cap
LossP/E TTM

AxoGen Inc

31.980
+0.280+0.88%
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison

TradingKey Stock Score of AxoGen Inc

Currency: USD Updated: 2025-12-19

Key Insights

AxoGen Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 5/208 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 35.20.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

AxoGen Inc's Score

Industry at a Glance

Industry Ranking
5 / 208
Overall Ranking
48 / 4582
Industry
Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Analyst Rating

Based on 10 analysts
Buy
Current Rating
35.200
Target Price
+14.32%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

AxoGen Inc Highlights

StrengthsRisks
Axogen, Inc. is focused on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. It offers repair solutions for surgeons and healthcare providers. Its portfolio of products includes Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard HA+ Nerve Protector, Axoguard Nerve Cap, and Avive+ Soft Tissue Matrix. Avance Nerve Graft is a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves. The Axoguard Nerve Connector is a porcine (pig) submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves. Axoguard Nerve Protector is a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments. Axoguard HA+ Nerve Protector consists of a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 35.18% year-on-year.
Undervalued
The company’s latest PE is -764.71, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 42.08M shares, increasing 0.02% quarter-over-quarter.
Held by PRFDX
Star Investor PRFDX holds 4.29K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 2.01.

Financial Health

Currency: USD Updated: 2025-12-19

The current financial score of AxoGen Inc is 8.56, ranking 34/208 in the Healthcare Equipment & Supplies industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 60.08M, representing a year-over-year increase of 23.51%, while its net profit experienced a year-over-year increase of 138.11%.

Score

Industry at a Glance

Previous score
8.56
Change
0

Financials

7.90

Key Metrics

Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.

Quality of Earnings

10.00

Operational Efficiency

8.56

Growth Potential

8.91

Shareholder Returns

7.43

AxoGen Inc's Company Valuation

Currency: USD Updated: 2025-12-19

The current valuation score of AxoGen Inc is 7.42, ranking 92/208 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is -764.71, which is -99.13% below the recent high of -6.64 and -4.19% above the recent low of -796.75.

Score

Industry at a Glance

Previous score
7.42
Change
0

Valuation Dimensions

P/E
P/B
P/S
P/CF
Industry Ranking 5/208
Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2025-12-19

The current earnings forecast score of AxoGen Inc is 8.40, ranking 38/208 in the Healthcare Equipment & Supplies industry. The average price target for AxoGen Inc is 36.00, with a high of 40.00 and a low of 27.00.

Score

Industry at a Glance

Previous score
8.40
Change
0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 10 analysts
Buy
Current Rating
35.200
Target Price
+14.32%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

90
Total
4
Median
7
Average
Company name
Ratings
Analysts
AxoGen Inc
AXGN
10
Boston Scientific Corp
BSX
36
Veeva Systems Inc
VEEV
34
Intuitive Surgical Inc
ISRG
34
Edwards Lifesciences Corp
EW
34
Thermo Fisher Scientific Inc
TMO
27
1
2
3
...
18

Financial Forecasting

EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-12-19

The current price momentum score of AxoGen Inc is 9.34, ranking 11/208 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 35.74 and the support level at 26.71, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score
9.32
Change
0.02

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators
Sell(1)
Neutral(3)
Buy(2)
Indicators
Value
Direction
MACD(12,26,9)
-0.326
Neutral
RSI(14)
68.222
Neutral
STOCH(KDJ)(9,3,3)
65.549
Buy
ATR(14)
1.868
High Vlolatility
CCI(14)
72.667
Neutral
Williams %R
33.531
Buy
TRIX(12,20)
1.047
Sell
StochRSI(14)
100.000
Overbought
Moving Average
Sell(0)
Neutral(0)
Buy(6)
Indicators
Value
Direction
MA5
30.840
Buy
MA10
30.598
Buy
MA20
29.874
Buy
MA50
24.454
Buy
MA100
20.188
Buy
MA200
16.952
Buy

Institutional Confidence

Currency: USD Updated: 2025-12-19

The current institutional shareholding score of AxoGen Inc is 10.00, ranking 1/208 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 97.83%, representing a quarter-over-quarter decrease of 3.81%. The largest institutional shareholder is The Vanguard, holding a total of 2.67M shares, representing 5.79% of shares outstanding, with 4.24% increase in holdings.

Score

Industry at a Glance

Previous score
10.00
Change
0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name
Shares Held
Chg %
First Light Asset Management, LLC
4.53M
+1.23%
BlackRock Institutional Trust Company, N.A.
3.10M
-0.84%
The Vanguard Group, Inc.
Star Investors
2.72M
+7.58%
Morgan Stanley & Co. LLC
1.93M
+21.98%
ArrowMark Colorado Holdings, LLC
1.63M
+2.19%
Soleus Capital Management, L.P.
1.46M
+0.92%
Wasatch Global Investors Inc
Star Investors
1.43M
+85.09%
Balyasny Asset Management LP
1.93M
+183.91%
Assenagon Asset Management S.A.
1.29M
+25.99%
Armistice Capital LLC
1.11M
+106.46%
1
2

Risk Assessment

Currency: USD Updated: 2025-12-19

The current risk assessment score of AxoGen Inc is 5.97, ranking 68/208 in the Healthcare Equipment & Supplies industry. The company's beta value is 0.99. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.

Score

Industry at a Glance

Previous score
5.97
Change
0
Beta vs S&P 500 index
0.99
VaR
+5.52%
240-Day Maximum Drawdown
+53.80%
240-Day Volatility
+70.03%

Return

Best Daily Return
60 days
+23.06%
120 days
+23.06%
5 years
+36.90%
Worst Daily Return
60 days
-7.59%
120 days
-9.04%
5 years
-23.18%
Sharpe Ratio
60 days
+3.99
120 days
+4.06
5 years
+0.45

Risk Assessment

Maximum Drawdown
240 days
+53.80%
3 years
+65.22%
5 years
+84.64%
Return-to-Drawdown Ratio
240 days
+2.22
3 years
+1.25
5 years
+0.13
Skewness
240 days
+0.59
3 years
+2.11
5 years
+1.50

Volatility

Realised Volatility
240 days
+70.03%
5 years
+66.84%
Standardised True Range
240 days
+2.91%
5 years
+2.06%
Downside Risk-Adjusted Return
120 days
+902.58%
240 days
+902.58%
Maximum Daily Upside Volatility
60 days
+69.79%
Maximum Daily Downside Volatility
60 days
+32.64%

Liquidity

Average Turnover Rate
60 days
+2.82%
120 days
+2.04%
5 years
--
Turnover Deviation
20 days
+201.03%
60 days
+124.18%
120 days
+62.69%

Peer Comparison

Healthcare Equipment & Supplies
AxoGen Inc
AxoGen Inc
AXGN
8.40 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Edwards Lifesciences Corp
Edwards Lifesciences Corp
EW
8.61 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
LivaNova PLC
LivaNova PLC
LIVN
8.59 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Artivion Inc
Artivion Inc
AORT
8.59 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Lantheus Holdings Inc
Lantheus Holdings Inc
LNTH
8.57 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Tactile Systems Technology Inc
Tactile Systems Technology Inc
TCMD
8.43 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more

FAQs

How does TradingKey generate the Stock Score of AxoGen Inc?

The TradingKey Stock Score provides a comprehensive assessment of AxoGen Inc based on 34 indicators derived from over 100 underlying data points.
These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of AxoGen Inc’s performance and outlook.

How do we generate the financial health score of AxoGen Inc?

To generate the financial health score of AxoGen Inc, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns.
By integrating these comprehensive data, the financial health score not only reflects AxoGen Inc's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of AxoGen Inc.

How do we generate the company valuation score of AxoGen Inc?

To generate the company valuation score of AxoGen Inc, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare AxoGen Inc’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value.
By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of AxoGen Inc’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of AxoGen Inc.

How do we generate the earnings forecast score of AxoGen Inc?

To calculate the earnings forecast score of AxoGen Inc, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:
Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.
Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.
By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.
Comparing these indicators against peers provides context for the stock’s performance and helps anchor more realistic expectations.
These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on AxoGen Inc’s future.

How do we generate the price momentum score of AxoGen Inc?

When generating the price momentum score for AxoGen Inc, we examine momentum indicators including support and resistance levels as well as volume metrics.
Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.
This comprehensive approach can reflect market sentiment and enable rational forecasts of AxoGen Inc’s prices. A higher score indicates a more stable short-term price trend for AxoGen Inc.

How do we generate the institutional confidence score of AxoGen Inc?

To generate the institutional confidence score of AxoGen Inc, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about AxoGen Inc’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of AxoGen Inc.

How do we generate the risk management score of AxoGen Inc?

To assess the risk management score of AxoGen Inc, we examine multiple key indicators related to returns, risk, volatility, and liquidity.
The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.
These indicators together provide a multi-dimensional understanding of AxoGen Inc’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of AxoGen Inc.
KeyAI